Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-7655A versus active comparator in hospitalized pediatric gram-negative bacterial infection
2019-000338-20Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of imipenem + cilastatin + relebactam in Gram-negative bacterial infection and bacterial disease (2 arms), sponsored by Merck & Co. Primary endpoint: Percentage of participants with one or more adverse event. Started Mar 2019; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
Gram-negative bacterial infectionbacterial disease
Beyond the preview
Go deeper on 2019-000338-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000338-20.